3- Aminobenzamide PARP inhibitor

PARP-1 in vitro. The insulator function of most of the same CTCF target sites was sensitive to the general PARP inhibitor 3-aminobenzamide. Collectively, these results support a role for PAR and PARP(s) in the activity of insulators, with an insulator-bound protein, possibly CTCF, as a target for PARylation. 

Human mononuclear leukocytes are a good model for studying SM-induced cytotoxicity. Niacinamide, 3-aminobenzamide, and PARP inhibitors have been shown to be... 

PARP inhibitors have been synthesized (11) and are shown in Figs. 11.4 and 11.5. Some of them have been tested in stroke models with good results in terms of preventing infarction (12-18). Most of the inhibitors are based on the structure of nicotinamide and therefore bind to the nicotinamide site of PARP. Several inhibitors are well known, such as nicotinamide, benzamide, and 3-aminobenzamide (19,20). However, new quinazolinone, phen-anthradinone, and other inhibitors are being investigated. Nicotinamide has a of about 5 xM for PARP (19). Activity is decreased in 6-aminonicotinamide, isonicotinamide, 1-methylnicotinamide, 5-methylnicotinamide, 8-methylnicotinamide, and thionicotinamide (Table 11.1 >... 

Figure 11.4. PARP inhibitors nicotinamide, 5-methylnicotinamide,6-aminonicotinamide,picolin-amide, 3-methoxybenzamide, benzamide, 3-aminobenzamide, 2-aminobenzamide, 4-aminobenz-amide, coumarin, 3,4-dihydro-5-methylisoquinolinone (PD 1287631, 4-amino-l,8-naphthalimide, 8-hydroxy-2-methyl-3-hydroquina2olin-4-one, phenanthridinone, and 3-0-allQ lbenzamides. This figure is redrawn from Ref 33 and is used with permission.

PARP inhibitors 3-aminobenzamide or nicotinamide. Importandy, a recent study, using clinical samples has confirmed the crucial importance of PARP activation in the pathogenesis of mitochondrial respiration and vascular dysfimcdon associated with sepsis. Human umbilical vein endothelial cells were incubated with serum firom healthy controls, patients with septic shock, or critically ill patients who were not septic. Endothelial cell mitochondrial respiration was significandy depressed by septic serum, which was abolished by pretreatment with the PARP inhibitor 3-aminobenzamide. ... 

Figure 21.1 The evolution of PARP inhibitors, (a) 3-Aminobenzamide (3-AB), (b) PJ34, (c) rucaparib, (d) veliparib, and (e) olaparib. The benzamide core structure of all PARP inhibitors is highlighted in bold.

Chemistry. Nicotinamide (NAm), a product of PARP-1 enzymatic action on NAD and a weak inhibitor of PARP-1 activity (Curtin, 2006), was used as a model for the first PARP-1 inhibitors, including benzamide and 3-aminobenzamide (3AB) (Shall, 1975) (Fig. 7a). Benzamide and 3AB inhibit PARP-1 activity in the mM range and may also inhibit other PARP family members e.g., PARP-2 and tankyrase Smith et al, 1998 Ame et al, 1999), thus lacking the potency and specificity required for therapeutic purposes. Banasik et al developed 1,5-dihydroisoquinoline (Fig. 7c) and a variety of other inhibitors (Banasik et al, 1992), which were used in turn to develop even more inhibitors with greater specificity. 

Figure 5 Structures of small-molecule inhibitors of nonapoptotic cell death. Inhibitors of (a-e) PARP-1, (f) HSP90, (i, j) mitochondrial respiratory complexes I and (k) complexes 2, (I) phosphatidylcholine-specific phospholipase C, (m) acid sphingomyelinase, (n) NADPH oxidase, (o) JNK kinase, (p-s) necroptosis, (t-w) MPTP, and (g, h) antioxidants, (a) 3-aminobenzamide, (b) benadrostin, (c) Nu1025, 8-hydroxy-2-methylquinazolin-4(3H)-one,...

Figure 43.6 IC50 value for TM34 inhibition compared to the reference benchmark PARP-1 inhibitor 3-aminobenzamide (3-AB) [29], cisplatin, and ruthenium complexes that exhibit antimetastatic activity in vivo NAMI-A and RAPTA-T (data for comparison taken from [30]). Adapted from Reference 11.

---